Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 612

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief intervention

Open access
Landewé, Robert B. M., Boers, Maarten, Verhoeven, Arco C., Westhovens, Rene, van de Laar, Mart A. F. J., Markusse, Harry M., van Denderen, J. Christiaan, Westedt, Marie Louise, Peeters, Andre J., Dijkmans, Ben A. C., Jacobs, Piet, Boonen, Annelies, van der Heijde, Désirée M. F. M., van der Linden, Sjef·2002·Arthritis & Rheumatism

Abstract

Objective: The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial demonstrated that step‐down combination therapy with prednisolone, methotrexate, and sulfasalazine (SSZ) was superior to SSZ monotherapy for suppressing disease activity and radiologic progression of rheumatoid arthritis (RA). The current study was conducted to investigate whether the benefits of COBRA therapy were sustained over time, and to determine which baseline factors could predict outcome. Methods: All patients had participated in the 56‐week COBRA trial. During followup, they were seen by their own rheumatologists and were also assessed regularly by study nurses; no treatment protocol was specified. Disease activity, radiologic damage, and functional ability were the primary outcome domains. Two independent assessors scored radiographs in sequence according to the Sharp/van der Heijde method. Outcomes were analyzed by generalized estimating equations on the basis of intent‐to‐treat, starting with data obtained at the last visit of the COBRA trial (56 weeks after baseline). Results: At the beginning of followup, patients in the COBRA group had a significantly lower mean time‐averaged 28‐joint disease activity score (DAS28) and a significantly lower median radiologic damage (Sharp) score compared with those in the SSZ monotherapy group. The functional ability score (Health Assessment Questionnaire [HAQ]) was similar in both groups. During the 4–5 year followup period, the time‐averaged DAS28 decreased 0.17 points per year in the SSZ group and 0.07 in the COBRA group. The Sharp progression rate was 8.6 points per year in the SSZ group and 5.6 in the COBRA group. After adjustment for differences in treatment and disease activity during followup, the between‐group difference in the rate of radiologic progression was 3.7 points per year. The HAQ score did not change significantly over time. Independent baseline predictors of radiologic progression over time (apart from treatment allocation) were rheumatoid factor positivity, Sharp score, and DAS28. Conclusion: An initial 6‐month cycle of intensive combination treatment that includes high‐dose corticosteroids results in sustained suppression of the rate of radiologic progression in patients with early RA, independent of subsequent antirheumatic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.10083

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 612

Metadata

Authors
Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., Jacobs, P., Boonen, A., van der Heijde, D. M. F. M., & van der Linden, S.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2002-02
Volume
46
Issue
2
Pages
347-356
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1982348705
Cited by
612
References
25
FWCI
25.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief intervention. https://app.cochat.ai/papers/10.1002/art.10083
The paper
Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., Jacobs, P., Boonen, A., van der Heijde, D. M. F. M., & van der Linden, S. (2002). COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief intervention. Arthritis & Rheumatism. https://doi.org/10.1002/art.10083

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.